Eagle Global Advisors’s AstraZeneca AZN Stock Holding History

Eagle Global Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$5.94M	Sell	36,766 -843	-2%	-$140K	0.2%	91
2026 Q2	$7.13M	Buy	37,609 +128	+0.3%	+$24.1K	0.24%	83
2026 Q1	$7.39M	Buy	37,481 +10,880	+41%	+$2.1M	0.27%	72
2025 Q4	$4.89M	Sell	26,601 -167	-0.6%	-$29.3K	0.18%	99
2025 Q3	$4.11M	Hold	26,768	–	–	0.16%	105
2025 Q2	$3.74M	Buy	26,768 +80	+0.3%	+$11.2K	0.15%	103
2025 Q1	$3.92M	Sell	26,688 -1,265	-5%	-$183K	0.16%	99
2024 Q4	$3.66M	Sell	27,953 -1,675	-6%	-$234K	0.15%	100
2024 Q3	$4.62M	Sell	29,628 -290	-1%	-$46.8K	0.23%	79
2024 Q2	$4.67M	Buy	29,918 +1,712	+6%	+$258K	0.25%	77
2024 Q1	$3.82M	Buy	28,206 +8,013	+40%	+$1.06M	0.22%	81
2023 Q4	$2.72M	Sell	20,193 -557	-3%	-$72.4K	0.16%	99
2023 Q3	$2.81M	Buy	20,750 +7,712	+59%	+$1.05M	0.18%	97
2023 Q2	$1.87M	Buy	13,038 +740	+6%	+$109K	0.12%	118
2023 Q1	$1.71M	Buy	+12,298	New	+$1.65M	0.12%	120

Other funds holding AZN

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

Vanguard Asset Management London, Ec4n 8af $162B AUM

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Primecap Management Pasadena, California $161B AUM 86.05% 1-Year Est. Return

Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return

Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

Eagle Global Advisors's AZN Position: Q3 2026 in Review

Eagle Global Advisors reduced its AstraZeneca (AZN) stake by 2.2% in Q3 2026, selling an estimated $140K and leaving 36,766 shares worth $5.94M. The position accounts for 0.2% of the portfolio, ranked #91.

Eagle Global Advisors first reported a position in AZN in Q1 2023 and has held it in 15 quarters since. The position peaked at $7.39M in Q1 2026. 1,222 funds tracked by Wall St. Rank hold AZN as of Q3 2026.

Eagle Global Advisors held 36,766 shares of AstraZeneca worth $5.94M as of Q3 2026.
Eagle Global Advisors sold 843 AstraZeneca shares in Q3 2026, an estimated $140K.
AstraZeneca made up 0.2% of Eagle Global Advisors's portfolio in Q3 2026, its #91 holding.
Eagle Global Advisors first reported a position in AstraZeneca in Q1 2023 and has held it in 15 quarters since.
Eagle Global Advisors's AstraZeneca position peaked at $7.39M in Q1 2026.
1,222 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2026.

Based on Eagle Global Advisors's 13F filing for Q3 2026, filed 2 Nov 2026.